**Supplemental Figure S1.** Adjusted dose-response associations between total cholesterol to high density lipoprotein cholesterol ratio and adjusted odds ratios for cardiovascular disease (CVD) hospitalisation and rehospitalisation in East Cambridge and Fenland (ECF) and RAPSID RAndomised controlled trial of Peer Support In type 2 Diabetes (RAPSID) cohorts: sensitivity analysis in the data rich range

Age, gender, systolic blood pressure, diastolic blood pressure, body mass index, HbA1c, low density lipoprotein cholesterol, and lipid lowering treatment were adjusted.

Supplemental Figure S2. Adjusted dose-response associations between total cholesterol to high density lipoprotein cholesterol ratio and adjusted odds ratios for cardiovascular disease (CVD) hospitalisation and rehospitalisation by gender in East Cambridge and Fenland (ECF) and RAPSID RAndomised controlled trial of Peer Support In type 2 Diabetes (RAPSID) cohorts: sensitivity analysis in the data rich range

Age, systolic blood pressure, diastolic blood pressure, body mass index, HbA1c, low density lipoprotein cholesterol, and lipid lowering treatment were adjusted.

Supplemental Table S1. Adjusted incidence rates ratios for cardiovascular disease (CVD) hospitalisation and re-hospitalisation in men and women by 1 unit increase in TC/HDL ratio in groups classified by TC/HDL threshold (2.8) in East Cambridge and Fenland (ECF) and RAPSID RAndomised controlled trial of Peer Support In type 2 Diabetes (RAPSID) cohorts

‡ *Indicates age was adjusted; * indicates age, systolic blood pressure, diastolic blood pressure, body mass index, HbA1c, low density lipoprotein cholesterol, and lipid lowering treatment were adjusted.*

	Men in ECF Cohort				Men in RAPSID Cohort			
	TC/HDL ratio ≤ 2.8 (n=1,028, (53.5%))	*P-value*	TC/HDL ratio > 2.8 (n=892, (46.5%))	*P-value*	TC/HDL ratio ≤ 2.8 (n=125, (28.1%))	*P-value*	TC/HDL ratio > 2.8 (n=320, (71.9%))	*P-value*
CVD Hospitalisation								
Hospitalisation, n (%)	93 (9.0)	-	121 (13.6)	-	15 (12.0)	-	46 (14.4)	-
Adjusted incidence rates ratio‡	0.97 (0.82 to 1.15)	0.134	1.12 (0.94 to 1.33)	<0.0001	1.02 (0.86 to 1.22)	0.200	1.17 (0.64 to 2.14)	0.015
Adjusted incidence rates ratio*	0.97 (0.83 to 1.14)	0.128	1.15 (0.95 to 1.38)	<0.0001	1.05 (0.87 to 1.27)	0.287	1.30 (0.72 to 2.35)	0.037
	Women in ECF Cohort				Women in RAPSID Cohort			
	TC/HDL ratio ≤ 2.8 (n=1,183, (42.5%))	*P-value*	TC/HDL ratio > 2.8 (n=1,601, (57.5%))	*P-value*	TC/HDL ratio ≤ 2.8 (n=144, (21.3%))	*P-value*	TC/HDL ratio > 2.8 (n=532, (78.7%))	*P-value*
CVD Hospitalisation								
Re-hospitalisation, n (%)	123 (10.4)	-	251 (15.7)	-	24 (16.7)	-	98 (18.4)	-
Adjusted incidence rates ratio‡	1.03 (0.90 to 1.17)	0.129	1.21 (1.08 to 1.36)	<0.0001	1.00 (0.65 to 1.54)	0.209	1.22 (1.00 to 1.49)	0.004
Adjusted incidence rates ratio*	1.00 (0.88 to 1.14)	0.104	1.25 (1.11 to 1.41)	<0.0001	0.93 (0.60 to 1.44)	0.320	1.20 (1.00 to 1.43)	0.003
	Men in ECF Cohort				Men in RAPSID Cohort			
	TC/HDL ratio ≤ 2.8 (n=1,028, (53.5%))	*P-value*	TC/HDL ratio > 2.8 (n=892, (46.5%))	*P-value*	TC/HDL ratio ≤ 2.8 (n=125, (28.1%))	*P-value*	TC/HDL ratio > 2.8 (n=320, (71.9%))	*P-value*
CVD Re-hospitalisation								
Hospitalisation, n (%)	40 (3.9)	-	72 (8.1)	-	8 (6.4)	-	19 (5.9)	-
Adjusted incidence rates ratio‡	0.93 (0.71 to 1.20)	0.202	1.19 (0.91 to 1.56)	<0.0001	1.04 (0.55 to 1.99)	0.816	1.05 (0.55 to 2.01)	0.028
Adjusted incidence rates ratio*	0.93 (0.72 to 1.22)	0.56	1.30 (0.98 to 1.73)	<0.0001	0.90 (0.46 to 1.76)	0.768	1.15 (0.61 to 2.18)	0.037
	Women in ECF Cohort				Women in RAPSID Cohort			
	TC/HDL ratio ≤ 2.8 (n=1,183, (42.5%))	*P-value*	TC/HDL ratio > 2.8 (n=1,601, (57.5%))	*P-value*	TC/HDL ratio ≤ 2.8 (n=144, (21.3%))	*P-value*	TC/HDL ratio > 2.8 (n=532, (78.7%))	*P-value*
CVD Re-hospitalisation								
Re-hospitalisation, n (%)	51 (4.6)	-	153 (9.6)	-	10 (6.9)	-	41 (7.7)	-
Adjusted incidence rates ratio‡	1.08 (0.88 to 1.31)	0.113	1.16 (0.97 to 1.38)	<0.0001	1.03 (0.66 to 1.62)	0.680	1.59 (1.24 to 2.05)	0.033
Adjusted incidence rates ratio*	1.04 (0.85 to 1.27)	0.143	1.22 (1.01 to 1.48)	<0.0001	1.01 (0.63 to 1.62)	0.716	1.55 (1.18 to 2.04)	0.026